A Phase I/II Study of Regorafenib and Pembrolizumab in Metastatic Colorectal Cancer Patients in 3rd and 4th Line Setting
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Oct 2019 Planned End Date changed from 1 Jul 2022 to 21 Jun 2022.
- 21 Oct 2019 Planned primary completion date changed from 1 Jul 2021 to 21 Jun 2021.
- 21 Oct 2019 Status changed from not yet recruiting to recruiting.